Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova reported Q1 FY26 consolidated revenue of ₹1,901 crore, up about 9.8% from ₹1,732 crore a year ago. Profit before exceptional items and tax rose nearly 49% to ₹154 crore, reflecting strong margin expansion across segments like Radiopharma (₹869 crore), CDMO Sterile Injectables (₹393 crore) and CRDMO (₹311 crore). However, reported net profit fell sharply to ₹103 crore (EPS ₹6.49) versus ₹482 crore last year, mainly because the prior year quarter included a one-time exceptional gain of about ₹396 crore that did not recur. On a standalone basis, the API business has been classified as discontinued operations ahead of its slump sale to wholly-owned subsidiary Jubilant Biosys Limited, expected to complete by September 1, 2025. Statutory auditor Walker Chandiok & Co LLP issued a clean limited review report with no qualifications on both sets of results.
The headline PAT drop looks negative on the surface, but the underlying business actually showed healthy revenue growth, stronger margins, and lower finance costs, suggesting core operations are improving. The API divestment simplifies the portfolio into focused, higher-margin businesses like Radiopharma and CDMO, which should be viewed positively by investors.